Observational studyCritical care medicine2017
Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study.
Observational study in Critical care medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 136 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mortality Due to Septic Shock Associated With Thrombocytopenia in the Intensive Care Unit
Procalcitonin at Zero and 24 Hours as a Prognostic Factor in Patients With Pneumonia
Who cites it
136 citing papers in PubMed, 5 syntheses or guidelines pooled it, 278 citations in OpenAlex.
- Long-term risk and predictors of cerebrovascular events following sepsis hospitalization: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Duration of antibiotic treatment using procalcitonin-guided treatment algorithms in older patients: a patient-level meta-analysis from randomized controlled trials.Age and ageing · 2021Pooled it
- Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis.Critical care (London, England) · 2019Pooled it
- Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials.Critical care (London, England) · 2018Pooled it
- Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.The Cochrane database of systematic reviews · 2017Pooled it
- Incremental Prognostic Value of Albumin-Anchored Inflammatory Ratios Beyond a SOFA-Based Model in a Medical ICU: A Retrospective Cohort Study.Metabolites · 2026Article
- Beyond Acute Kidney Injury : Direct Pathways Implicate Inflammatory Mechanisms in Serum NGAL's Mortality Effect in Acute Brain Injury.Translational stroke research · 2026Article
- Prognostic Value of 72-h Reassessment Using SOFA Score, C-Reactive Protein, and Lactate in a 72-h Landmark Cohort of Intensive Care Patients with Gram-Negative Sepsis.Medicina (Kaunas, Lithuania) · 2026Article
- Association between 30-day mortality and serially measured hematologic markers in patients with septic shock in South Korea.Acute and critical care · 2026Article
- The molecular ICU: a primer on omics, informatics and the future of precision critical care.Critical care (London, England) · 2026Review
- Evaluation of sequential serum amyloid A measurements for the prediction of sepsis and survival in critically ill neonatal foals.Journal of veterinary internal medicine · 2026Article
- Diagnostic performance of procalcitonin for predicting bloodstream infection and guidance on microbial aetiology: a prospective study at an Egyptian tertiary care hospital.BMC infectious diseases · 2026Article
- Prognostic Value of 48-Hour Biomarker Reassessment Beyond Admission SOFA for 28-Day Mortality in Sepsis.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Comparison of serial pancreatic stone protein, C-reactive protein and procalcitonin for the diagnosis of infection and sepsis in critically Ill patients: a multicentre prospective study.BMC anesthesiology · 2026Article
- Pathway-level profiling of the sepsis proteome reveals immune and transcriptional dysregulation.Molecular medicine (Cambridge, Mass.) · 2026Article
- Assessment of Systemic Inflammation as a Tool for Estimating the Risk of Death by Visceral Leishmaniasis.Pathogens (Basel, Switzerland) · 2026Article
- Evaluation of Neutrophil-to-Lymphocyte Ratio and CRP-to-Albumin Ratio in the Risk Stratification of Diabetic Foot Infection Severity.Medicina (Kaunas, Lithuania) · 2026Article
- ABO Blood Group and Biomarker-Based Risk in Acute Pulmonary Embolism: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- The Global Impact of Sepsis: Epidemiology, Recognition, Management, and Health System Challenges.Epidemiologia (Basel, Switzerland) · 2026Review
76 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
16 authors at 10 institutions in 2 countries.
Funding
Abstract
objectivesTo prospectively validate that the inability to decrease procalcitonin levels by more than 80% between baseline and day 4 is associated with increased 28-day all-cause mortality in a large sepsis patient population recruited across the United States.
designBlinded, prospective multicenter observational clinical trial following an Food and Drug Administration-approved protocol.
settingThirteen U.S.-based emergency departments and ICUs. PATIENTS: Consecutive patients meeting criteria for severe sepsis or septic shock who were admitted to the ICU from the emergency department, other wards, or directly from out of hospital were included.
interventionsProcalcitonin was measured daily over the first 5 days. MEASUREMENTS AND MAIN
resultsThe primary analysis of interest was the relationship between a procalcitonin decrease of more than 80% from baseline to day 4 and 28-day mortality using Cox proportional hazards regression. Among 858 enrolled patients, 646 patients were alive and in the hospital on day 4 and included in the main intention-to-diagnose analysis. The 28-day all-cause mortality was two-fold higher when procalcitonin did not show a decrease of more than 80% from baseline to day 4 (20% vs 10%; p = 0.001). This was confirmed as an independent predictor in Cox regression analysis (hazard ratio, 1.97 [95% CI, 1.18-3.30; p < 0.009]) after adjusting for demographics, Acute Physiology and Chronic Health Evaluation II, ICU residence on day 4, sepsis syndrome severity, antibiotic administration time, and other relevant confounders.
conclusionsResults of this large, prospective multicenter U.S. study indicate that inability to decrease procalcitonin by more than 80% is a significant independent predictor of mortality and may aid in sepsis care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.